Prevagen. Healthier brain. Better life.
MARIA: WILL COME BACK THE
DISTRIBUTION OF THE JOHNSON &
JOHNSON COVID-19 VACCINE ON
PAUSES WE CAN AS A CDC PANEL
INVESTIGATES POTENTIAL LINKS TO
A RARE BLOOD CLOT DISORDER.
JOIN AMY FOX BUSINESS EXCLUSIVE
ANOTHER MAKER OF COVID-19
VACCINE THE CEO OF MODERNA IS
HERE, STÉPHANE BANCEL.
GREAT TO SEE YOU THIS WEEKEND,
THANK YOU VERY MUCH FOR JOINING
US.
I WANT TO START OFF WITH YOUR
REACTION TO THE LATEST
DEVELOPMENTS ABOUT THE BLOOD
CAUSING, WHAT YOU KNOW ABOUT
THIS, PEOPLE ARE WORRIED ABOUT
VACCINES IN GENERAL.
>> GOOD MORNING AND THANK YOU
FOR HAVING ME.
WE ARE MONITORING SAFETY VERY
CAREFULLY AND WE HAVE SINCE THE
VACCINE IS BEEN AUTHORIZED IN
DECEMBER.
WE ARE WATCHING CLOSELY IN THE
CDC IS VERY REGULATED.
THE GOOD NEWS SO FAR YOU HAVE
THE VACCINE IN THE PHASE THREE
STUDY, WE ARE NOW 63 MILLION
PEOPLE OF DATA SO IT’S A BIG
NUMBER.
I THINK THE GOOD NEWS OF WHAT’S
HAPPENING TODAY GIVES THE
AMERICAN PEOPLE FEELING GREAT
ABOUT THE CDC AND THE SAFETY OF
AMERICAN CITIZENS.
VERY SERIOUSLY.
AND ANY THING NEEDS TO BE
INVESTIGATED TO MAKE SURE THE
VACCINES CAN BE USED SAFELY.
I BELIEVE AND TRUST THE
SCIENTIST AND ADVISORS TO DO THE
RIGHT THING FOR THE AMERICAN
PEOPLE.
MARIA: YOU MAKE A GREAT POINT IN
EUROPE TO BE CONGRATULATED, I
WANT TO THANK YOU ON BEHALF OF
ALL OF OUR VIEWERS WHO HAVE
GOTTEN VACCINATED AND PLANNING
ON IT, YOU DID THIS IN WARP
SPEED, YOU GOTTA VACCINE ON THE
MARKET AND REALLY LIFTED THE
PUBLIC UP.
THANK YOU TO YOU AND YOUR
SCIENTIST FOR THIS INCREDIBLE
PERFORMANCE, PEOPLE NOW ARE
WORRIED ABOUT SIDE EFFECTS AND
THE NEED FOR ANOTHER BOOSTER
SHOT, WHAT ARE YOUR THOUGHTS ON
THIS, HOW MUCH EFFICACY CAN WE
EXPECT AFTER GETTING VACCINATED
WITH MODERNA VACCINE.
>> GREAT QUESTION, ON THE
EFFICACY WE ANNOUNCED THIS WEEK
THAT THE SIX-MONTH BOOST WITH
THE PHASE THREE STUDY AND IT WAS
60000 PEOPLE AND WE HAVE SEEN
NORTH OF 90% AND THE VACCINE
SEEMS TO BE DOING REALLY WELL IN
THE REAL WORLD AND AS YOU KNOW
WE HAVE VARIANCE IN THE
COMMUNITY AND VERY CONFIDENT
ABOUT A VACCINE TO ADVISE PEOPLE
GIVEN THE RISK OF LUNG DISEASE
AND AUTHORIZATION AND A CONTROL
SO WE COULD GO BACK TO OUR NORMAL LIVES AND BE WITH THEIR
LOVED ONES AND TRAVELING IN THE
VARIANT IS GOING TO BE THE BIG
QUESTION AND I THINK TWO THINGS
TO THINK ABOUT.
ONE IS NATURAL WINNING IMMUNITY
YOU MAKE ANTIBODIES OR YOU GET
VACCINATED AND MAKE ANTIBODIES,
OVER TIME THE LEVEL OF
ANTIBODIES GOING TO GO DOWN,
THAT IS NORMAL AND NATURAL, OVER
TIME BOOSTER GOING TO BE
REQUIRED, IT IS TOO EARLY TO
KNOW BECAUSE WE DON’T HAVE
ENOUGH DATA.
MARIA: THE VARIANCE ARE
WORRISOME BECAUSE WE DON’T KNOW
HOW SEVERE THEY ARE.
>> CORRECT AND WE DON’T KNOW HOW
THEY WILL IMPACT IN THE LONG
TERM EFFICACY.
IN THE SHORT TERM WE ARE NOT
WORRIED THE B117 THE FIRST EVER
IN THE UK WHICH IS PROMINENT IN
THE U.S. NOW WE HAVE SEEN AND
PUBLISHED THAT THE ANTIBODY IS
SIMILAR TO AN OLD STRAIN OF THE
VIRUS.
WE FEEL VERY GOOD ABOUT THIS
ONE.
AND THE ONE IDENTIFIED IN SOUTH
AFRICA, WE SEE A DROP OF THE
ANTIBODY BUT WAY HIGHER THAN THE
ANTIBODY THAT GETS INFECTED.
SO WE BELIEVE PEOPLE WILL BE
PROTECTED AGAINST THOSE IN THE
SHORT TERM, WHAT IS IMPOSSIBLE
IS NEXT WINTER WITH THE VARIANCE
OR NEW VARIANCE WHICH IS WHY WE
BELIEVE THAT BOOSTING IS GOING
TO BE REALLY IMPORTANT TO KEEP
THE COUNTRY SAFE AND OPEN AND WE
ARE WORKING, AND 30 DAYS MODERNA
DEVELOPED OVARIAN BOOST OF
FORMER SOUTH AFRICAN STRAIN, WE
HAVE THE DATA SHOWN IT WORKS
VERY WELL IN HUMAN DATA VERY
SOON.
MARIA: I SEE, LET ME ASK YOU
WITH REGARD TO THE BLOOD
CLOTTING THAT WE ARE HEARING
ABOUT FROM JOHNSON & JOHNSON IN
THE WALL STREET JOURNAL REPORTED
THIS WEEK THE DAY AND A
PRIVATELY REACHED OUT TO OTHER
COVID-19 MAKERS TO SAY, PFIZER
IN MODERNA, LET’S JOIN EFFORTS
TO LOOK INTO THE REPORTS OF
BLOOD CLOTTING, LET’S DO A
LITTLE BIT MORE OF A DEEP DIVE
ON THE BLOOD CLOTTING RISKS, J&J
THROUGH E-MAIL AND PHONE CALLS
WITH THE WALL STREET JOURNAL
SAID THAT THEY TRIED TO BUILD AN
INFORMAL ALLIANCE AMONG ALL OF
THOSE COMPANIES, YOUR THOUGHTS
ON THAT, DID YOU DECLINE, WHAT
HAPPENED.
>> WE COMMUNICATE TO REGULATORS,
THE FDA AND THE CDC AND OF
COURSE TO THE U.S. GOVERNMENT ON
A DAILY BASIS, WE SHARE ALL THE
DATA AS WE HAVE TO, THERE’S A
HIGH LEVEL OF CORPORATION AND WE
BELIEVE THE REGULATORS TO
COORDINATE TOGETHER AND COMPARE
THE DATA, I DON’T THINK IT IS
SOMETHING THE INDUSTRY SHOULD BE
DOING I THINK THEY’RE DOING A
WE WERE TALKING ABOUT THE
BREADTH OF THE COMPANY BEFORE WE
WENT TO THE BREAK, I WANT TO
TALK ABOUT THE VACCINE THAT YOU
HAVE THIS WEEK A NUMBER OF
ANALYSTS ARE TALKING ABOUT THE
GROWTH POTENTIAL FORMER MODERNA,
TELL US WHAT YOU REVEALED IN
TERMS OF THE COVID-19’S
SITUATION AND I WOULD LIKE TO
TALK ABOUT THE IMPACT OF THIS
VACCINE TO HIGHLIGHT THE OTHER
THINGS THAT YOU’RE WORKING ON IN
THE PIPELINE AT MODERNA.
>> ON THE COVID-19, WE JUST
TALKED ABOUT WHICH IT IS VERY
HIGH IN A SIX-MONTH IT IS VERY
HIGH IN THE VARIANT WHICH IS
BEING TESTED AS A BOOST IN
ANIMAL TESTING AND VERY SOON IN
THE SPRING AND WHAT WE EXPECT TO
SEE IN THE SIZE OF THE STUDY AND
THE INPUT OF A STUDY AND WE ARE
HOPEFUL THAT NO LATER THAN EARLY
SUMMERENTER LEADER SUMMER EARLY
AUTHORIZED SO NEXT FALL OR NEXT
WINTER.
THE REST OF THE PIPING, AND
TRADITIONAL PHARMACEUTICALS EVERY DRUG IS A DIFFERENT DRUG
MRNA IS LIKE SOFTWARE IT CAUSES
EVERY MRNA UNDER THE CENTER MAKE
PROTEIN IN YOUR BODY.
WE HAVE NINE VACCINES AND MOST
OF THE VACCINES, THERE VACCINES
AGAINST THE VIRUS IN WHICH THERE
IS NO VACCINE ON THE MARKET.
THERE ARE FLU VACCINES BUT AS
REPORTED IN THE GOODYEAR YOU GET
62% WHICH IS NOT GREAT AND IN A
BAD YEAR YOU GET 20 OR 30%
EFFICACY WE BELIEVE WE CAN AGREE
TO MRNA IS 90% AGAINST THE FLU
VACCINE.
YOU STILL COMBINE THE COVID
BOOST WITH THE FLU VACCINE AND
DO ONE SINGLE DOSE SO YOU CAN GO
TO YOUR CVS OR GP AND GET ONE
DOSE, THAT’S WHATEVER VARIANT OF
COPING AND FOR THAT WINTER YOU
CAN HAVE A SAFE WINTER, THAT’S
ANOTHER PIECE WE TALKED ABOUT.
AND TO DISRUPT THE CURRENT
MARKET I THINK A LOT OF PEOPLE
THAT DO NOT TAKE A FLU SHOT
BECAUSE THEY WORRY ABOUT LACK OF
EFFICACY, WE IN THE FUTURE WHAT
WHAT -- AS YOU KNOW BEFORE COVID
60000 PEOPLE IN THIS COUNTRY
BECAUSE OF FLU AND MANY DAYS OF
WORK LOST IN WITH FAMILY AND
FRIENDS AND VACATION LOST, WE
CAN HAVE A BIG DENT ON THIS
VIRUS WITH OUR PLATFORM.
MARIA: AWARD ON CANCER AND HIV
VACCINE THIS IS PART OF THE GROWTH STORY AT THE VACCINE DAY
THIS WEEK.
>> MANY ON THE COUNTRY OF A
VACCINE THAT SOME ARE VERY
PROMISING IN 40 YEARS AFTER THE
DISCOVERY OF HIV AND AIDS WE
STILL NEED A VACCINE TO PROTECT
PEOPLE AGAINST HIV WE HAVE A
CLINICAL TRIAL AGAINST SKIN
CANCER, BREAST CANCER, BRAIN
CANCER AND MANY MORE, WE HAVE A
DRUG, THAT’S BEEN INJECTED INTO
PEOPLE’S ARMS AS A ONE
INTERVENTION.
IT’S ABOUT TEN MINUTES.
IN THE MRNA TO IT GROW NEW BLOOD VESSELS, WE BRING OXYGEN AND
NUTRIENTS SO IF YOU HAVE A HEART
ATTACK, YOU CAN HAVE A GOOD
QUALITY OF LIFE WITHOUT HAVING A
HEART FAILURE.
MARIA: IT’S BEEN AN INCREDIBLE